These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10950468)

  • 1. Paranoid/belligerence and neuroleptic dosage in newly admitted schizophrenic patients.
    Troisi A; Pasini A; de Angelis F; Spalletta G
    J Clin Psychopharmacol; 1997 Apr; 17(2):84-7. PubMed ID: 10950468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
    Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
    Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic drug utilisation for acute schizophrenia.
    Razali MS; Hasanah CI
    Singapore Med J; 1996 Dec; 37(6):611-3. PubMed ID: 9104062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G; Annable L; Jones BD; Collu R
    Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of smoking on neuroleptics in schizophrenia.
    Salokangas RK; Saarijärvi S; Taiminen T; Lehto H; Niemi H; Ahola V; Syvälahti E
    Schizophr Res; 1997 Jan; 23(1):55-60. PubMed ID: 9050128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
    Sramek JJ; Simpson GM; Morrison RL; Heiser JF
    J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cortisol and DHEA-S levels in schizophrenic patients with different response to antipsychotic therapy: association with psychopathology.
    Babinkostova Z; Stefanovski B; Janicevic-Ivanovska D; Samardziska V; Stojanovska L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):175-83. PubMed ID: 26076787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.
    Linden M; Scheel T; Xaver Eich F
    Hum Psychopharmacol; 2004 Mar; 19(2):111-9. PubMed ID: 14994321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis.
    Salokangas RK
    Schizophr Res; 1995 Jul; 16(1):7-16. PubMed ID: 7547647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic dose reduction in older psychotic patients.
    Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
    Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.
    Lane HY; Chang YC; Chiu CC; Lee SH; Lin CY; Chang WH
    Psychopharmacology (Berl); 2004 Apr; 172(4):393-9. PubMed ID: 14663551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
    Leblanc G; Cormier H; Gagné MA; Vaillancourt S
    Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive states occurring during the neuroleptic treatment of schizophrenia.
    Möller HJ; von Zerssen D
    Schizophr Bull; 1982; 8(1):109-17. PubMed ID: 6122264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender and the use of neuroleptics in schizophrenia.
    Salokangas RK
    Schizophr Res; 2004 Jan; 66(1):41-9. PubMed ID: 14693351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Principles of chemotherapy of paranoid schizophrenia].
    Vanelle JM; Loloum T
    Encephale; 1991; 17(4):235-40. PubMed ID: 1683623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.